I was born in Taipei and raised by my grandparents in southern Taiwan until I was five, when I moved to Long Island with my mom. She raised me on her own, and I think that's where I got my drive — I just wanted to do everything. Violin, Science Olympiad, golf, tennis, every club and activity I could find.
I spent 11 years at Stanford. Biology undergrad, medical school, internal medicine residency — plus every hackathon, workshop, and entrepreneurship program I could squeeze in. I matched into a hematology-oncology fellowship at Columbia. Cancer ran deep on my mom's side — six relatives, many of whom died from it — and I wanted to do something about it.

But I left the fellowship to build startups.

I wanted to reach millions of people, not one patient at a time. My early ventures taught me how to move fast. Then came Curio — my first VC-backed company, built during COVID, which grew into a psychedelic-assisted therapy platform across five states. We helped people through some of the hardest moments of their lives.
So why longevity?
While I was working on my startup, my dad had a massive heart attack back in Taiwan. He was resuscitated and spent over a month in a medical coma. While he was unconscious, his father passed away. That same year, my aunt died of an aortic dissection. My dad eventually got a heart transplant in 2025 — he's recovering, thankfully.
I'd spent my whole career thinking about cancer. Heart disease wasn't even on my radar. Then I got a full checkup and my ApoB — one of the strongest predictors of cardiovascular risk — came back at 128. I was a healthy woman in my mid-thirties. If a Stanford-trained physician didn't know her own risk, what chance does everyone else have?
That changed everything. I started The Longevity Show and The Longevity Letter to make the science accessible. I built a concierge longevity practice. I started speaking at conferences alongside researchers I'd only ever read about. And in 2025, I founded CareCore — an AI-powered platform that brings clinical-grade longevity medicine to clinicians and creators at scale.
There's still so much to build.






